Telaprevir: Added benefit in certain patients with hepatitis C

Probability of added benefit varies / Extent of added benefit partly unclear / Also indications of greater harm

2012-09-05

(Press-News.org) The drug telaprevir (trade name: Incivo®) has been available for treatment of chronic hepatitis C infection of genotype 1 since autumn 2011. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether telaprevir offers an added benefit compared with the present standard therapy.

According to the findings of the assessment, the new drug telaprevir offers advantages in various groups of patients with chronic hepatitis C infection of genotype 1. The available studies provide proof, indications or "hints" of an added benefit. However, not only the probability but also the extent of added benefit varies.

An addition to previous standard drug therapy

Hepatitis C viruses attack the liver and can trigger inflammation there. If this becomes chronic, cirrhosis can develop and liver function progressively deteriorates. Moreover, the risk of liver cancer (hepatocellular carcinoma, HCC) increases. The virostatic drug telaprevir inhibits the reproduction of hepatitis C viruses. Experts assume that if no viruses are detectable in the blood over a sustained period after treatment (sustained virological response, SVR), the risk of secondary disease is reduced.

Telaprevir is administered in addition to peginterferon alfa (immune-system enhancing drug) and ribavirin (virostatic drug), which are already on the market. In accordance with the approval status, different patient groups are treated for different periods, which was allowed for in the assessment. The dual combination of peginterferon alfa and ribavirin is the present standard therapy, and this was compared with the triple combination of these two standard drugs and telaprevir.

Studies largely only provide data on morbidity and adverse effects

Overall 3 relevant studies were identified. The outcomes considered were "mortality", "secondary complications of treatment (morbidity)", measured in the studies by means of the surrogate outcome "SVR", as well as "health-related quality of life" and "adverse effects".

The quality-of-life results for treatment-naïve (i.e. previously untreated) patients without cirrhosis were not statistically significant. No evaluable data on this outcome were available for other patient groups. Due to the too short study duration, the event rates for mortality were too low in all patient groups to be able to draw robust conclusions.

Extent of added benefit cannot be classified on the basis of the surrogate outcome for morbidity

The extent of added benefit cannot be classified on the basis of the surrogate outcome "SVR". This parameter is not a patient-relevant outcome in itself and there are no studies in which SVR is validated as a surrogate outcome in accordance with the usual criteria employed by IQWiG. Nevertheless, the Institute accepts SVR in the context of this assessment as a surrogate for the reduced incidence of liver cancer. This is because it is currently accepted that patients with no detectable hepatitis C virus in the blood are at lower risk of liver cancer. However, it is not known how many cases of liver cancer can in fact be prevented by telaprevir and it is therefore unclear whether the added benefit can be classified as "minor" "considerable" or "major".According to the corresponding legal ordinance, the added benefit is thus "unquantifiable".

Under consideration of the beneficial and harmful effects of telaprevir, overall IQWiG reaches different conclusions for different patient groups.

Advantages for treatment-naïve patients without cirrhosis who have a high viral load

Different results for morbidity were shown for treatment-naïve patients without cirrhosis, depending on the viral load in the blood at the start of treatment. Proof of an added benefit of telaprevir was only determined for patients with a high viral load. However, the extent of the added benefit is unquantifiable as it refers to the surrogate outcome "SVR".

For treatment-naïve patients without cirrhosis, the data also provide proof and an indication of greater harm due to the adverse effects "anaemia" and "rash" respectively, the extent being classified as "considerable" in the former and "minor" in the latter case. In the consideration of the beneficial and harmful effects of telaprevir, this did not lead to a restriction in the overall conclusion for patients with a high viral load, as these side effects were nearly exclusively classified as "not serious".

In contrast, for treatment-naïve patients without cirrhosis who have a low viral load at baseline, the data provide an indication of lesser benefit of telaprevir versus the comparator therapy. This is due to the fact that an added benefit regarding SVR is not proven, so that only the harmful effects are taken into account.

An added benefit of telaprevir is not proven for treatment-naïve patients with cirrhosis, as the manufacturer dossier did not contain any evaluable data.

Indication of an advantage also in patients with unsuccessful pre-treatment

Depending on the cirrhosis status, different results were shown for patients in whom treatment had so far been unsuccessful (non-responders). Regarding morbidity, the data provide an indication of an added benefit of telaprevir in patients without cirrhosis. The data only provide a "hint" of an added benefit in non-responders with cirrhosis. In this context, "indication" and "hint" refer to the surrogate outcome "SVR". Therefore the extent of added benefit is unquantifiable.

As in the case of treatment-naïve patients without cirrhosis, indications of greater harm due to the side effects "anaemia" and "rash" did not lead to a restriction in the overall conclusion.

No additional benefit for relapsed patients

In patients without cirrhosis who relapsed after standard therapy, the treatment regimen deviated from the approval status. Consequently, the added benefit cannot be assessed on the basis of the available data so that an added benefit is not proven.

In patients with cirrhosis who relapsed, the data provide an indication of an added benefit regarding SVR. However, at the same time they also provide an indication of greater harm (extent: considerable) regarding serious adverse events. Under consideration of the beneficial and harmful effects of telaprevir, IQWiG concluded that overall an added benefit is not proven for this patient group.

G-BA decides on the extent of added benefit

The procedure for inferring the overall conclusion on the extent of added benefit is a proposal from IQWiG. The G-BA, which has opened a formal commenting procedure, decides on the extent of added benefit.

###The website gesundheitsinformation.de, which is issued by IQWiG, provides easily understandable brief information (German version).

The G-BA website contains both general information on benefit assessments pursuant to §35a Social Code Book V and specific information on the assessment of telaprevir (German version).

ELSE PRESS RELEASES FROM THIS DATE:

New study examines how ocean energy impacts life in the deep sea

2012-09-05

Durham, NC — A new study of deep-sea species across the globe aims to understand how natural gradients in food and temperature in the dark, frigid waters of the deep sea affect the snails, clams, and other creatures that live there. Similar studies have been conducted for animals in the shallow oceans, but our understanding of the impact of food and temperature on life in the deep sea — the Earth's largest and most remote ecosystem — has been more limited. The results will help scientists understand what to expect in the deep sea under future climate change, the researchers ...

Gender equality influences how people choose their partners

2012-09-05

Men and women clearly have different strategies for picking sexual partners, but the reason why differences exist is less clear. The classic explanation for these differences has been that men's and women's brains have evolved to make certain choices, but a new study in Psychological Science, a publication of the Association for Psychological Science, suggests that evolution is only part of the answer. To be a 'success' in evolutionary terms, women need to have access to resources for raising offspring, and men need to have access to fertile females. Researchers have ...

AGU: Glacial thinning has sharply accelerated at major South American icefields

2012-09-05

WASHINGTON –For the past four decades scientists have monitored the ebbs and flows of the icefields in the southernmost stretch of South America's vast Andes Mountains, detecting an overall loss of ice as the climate warms. A new study, however, finds that the rate of glacier thinning has increased by about half over the last dozen years in the Southern Patagonian Icefield, compared to the 30 years prior to 2000. "Patagonia is kind of a poster child for rapidly changing glacier systems," said Michael Willis, lead author of the study and a research associate at Cornell ...

Teens tell different tales about themselves depending on gender

2012-09-05

COLUMBIA, Mo. — During adolescence, the stories young people tell about themselves reflects their development of a personal identity and sense of self, and those autobiographical narratives vary depending on the teens' gender, according to a University of Missouri psychologist and her colleagues. Parents can use this knowledge of how teens talk about themselves to help understand the tumultuous transitions of their children into adults. "Autobiographical stories tell us details about adolescent psychology that questionnaires and observations of behavior cannot," said ...

Study in mice discovers injection of heat-generating cells reduces belly fat

2012-09-05

COLUMBUS, Ohio – The injection of a tiny capsule containing heat-generating cells into the abdomens of mice led those animals to burn abdominal fat and initially lose about 20 percent of belly fat after 80 days of treatment. Researchers conducting the study were surprised to see that the injected cells even acted like "missionaries," converting existing belly fat cells into so-called thermogenic cells, which use fat to generate heat. Over time, the mice gained back some weight. But they resisted any dramatic weight gain on a high-fat diet and burned away more than ...

Study: How a high-fat diet and estrogen loss leads women to store more abdominal fat than men

2012-09-05

COLUMBUS, Ohio – A high-fat diet triggers chemical reactions in female mice that could explain why women are more likely than men to gain fat in the abdomen after eating excess saturated fat, new research suggests. The study also sheds light on why women gain fat following menopause. Scientists identified events in female mice that start with the activation of an enzyme and end with the formation of visceral fat – fat that accumulates around internal organs and is linked to a higher risk for Type 2 diabetes, heart disease and cancer. At least one function for this ...

Young Crossover Tenor Carlos Aponte Releases His Album: Attimo

2012-09-05

Puerto Rican Young Crossover Tenor Carlos Aponte recently presented 'Attimo', an album that features 11 of the world's most memorable songs with new musical and vocal arrangements in English, Spanish, Italian, and German. Since his appearance on the acclaimed NBC TV show America's Got Talent, Carlos has been busy at public and private performances in Puerto Rico, the United States and also internationally such as Costa Rica and China. 'Attimo' (Italian for 'Moment') includes a Spanish version of the smash hit 'You Raise Me Up (Por Ti Sere),' as well as other outstanding ...

Rate of women with pregnancy-associated cancer on the increase

2012-09-05

The rate of pregnancy-associated cancer is increasing and is only partially explained by the rise in older mothers suggests new research published today (5 September) in BJOG: An International Journal of Obstetrics and Gynaecology. A large Australian study looked at 781,907 women who gave birth in New South Wales (NSW) between 1994 and 2008 which corresponds to 1,309,501 maternities. Women with pregnancy-associated cancer, where the initial diagnosis of cancer is made during pregnancy or within 12 months of delivery, are compared to women without cancer. A total of ...

Rapid response in cases of smoke poisoning

2012-09-05

The main cause of cyanide poisoning is smoke inhalation in closed spaces during fires. Cyanides, the salts of hydrocyanic acid, inhibit cellular respiration and may lead to coma or death. The rapid administration of a cyanide antidote is essential for successful treatment. Previously, detecting cyanide in the blood took up to an hour and could only be performed in the laboratory, a lengthy process that is poorly suited for emergency situations. As a result, emergency doctors and paramedics are forced to administer antidotes based solely on presumptive diagnoses. Now, chemists ...

Syrian obsidian discovery opens new chapter in Middle Eastern studies

2012-09-05

An archaeologist from the University of Sheffield has revealed the origin and trading routes of razor-sharp stone tools 4,200 years ago in Syria. Ancient sites and cultural heritage are under threat in Syria due to the current conflict. An interdisciplinary research team hopes this new discovery, which has major implications for understanding the world's first empire, will help to highlight the importance of protecting Syria's heritage. Obsidian, naturally occurring volcanic glass, is smooth, hard, and far sharper than a surgical scalpel when fractured, making it a ...

Telaprevir: Added benefit in certain patients with hepatitis C

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: